Strona główna・Stock List・CytomX Therapeutics Inc

CytomX Therapeutics Inc

Closed

SectorHealthcare

3.55 5.03

Buy Sell

Overview

Share price change

24h

Current

Min

3.29

Max

3.43

Key metrics
By Trading Economics
Income	-2.4M -21M
Sales	-8.8M 1.4M
P/E Sector Avg	22.5 57.371
EPS	-0.09
Profit margin	-1,457.405
Employees	69
EBITDA	-2.4M -20M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+238.26% upside

Dividends
By Acuity
Next Earnings	5 lis 2026

Market Stats
By TradingEconomics
Market Cap	62M 752M
Previous open	-1.48
Previous close	3.55

News Sentiment

By Acuity

80%

20%

322 / 340 Ranking in Healthcare

CytomX Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

14 sie 2026, 19:36 UTC

Social Media

CytomX Therapeutics is higher as social media highlights its undervaluation, with a suggested price target of $6-7 ahead of year-end data releases.

13 sie 2026, 22:01 UTC

CytomX Therapeutics shares are higher in after-market trading, supported by broader market strength and a record closing high for the S&P 500.

12 sie 2026, 19:46 UTC

CytomX Therapeutics Inc shares are higher today, continuing an upward trend since Tuesday's close, supported by positive sentiment from the recent inflation report.

11 sie 2026, 23:21 UTC

CytomX Therapeutics Inc. shares are higher in after-market trading, reaching 1.45% above Tuesday's close amid strong performance relative to its moving average.

10 sie 2026, 23:31 UTC

CytomX Therapeutics Inc shares are lower in after-market hours after earlier volatility. Broader market sentiment remains cautious amid geopolitical tensions in the Strait of Hormuz.

7 sie 2026, 19:16 UTC

Social Media

News

CytomX Therapeutics expands collaboration with Regeneron on immunotherapies and updates on Varseta-M program, boosting sentiment amid a rising Biotechnology sector.

6 sie 2026, 22:02 UTC

Social Media

News

CytomX Therapeutics shares declined in after-market hours following a significant revenue miss of $1.418 million against expectations of $12.308 million.

31 lip 2026, 20:06 UTC

CytomX Therapeutics Inc shares declined sharply during Friday's session, reversing earlier gains and trading well below the 20-day moving average. No specific news was identified.

29 lip 2026, 19:47 UTC

CytomX Therapeutics shares are lower as traders await the Federal Reserve's interest rate decision, contributing to mixed performance across major U.S. indices.

28 lip 2026, 17:46 UTC

CytomX Therapeutics shares are lower today, reflecting a broader cautious tone across Asian markets. The stock remains near its one-month low.

27 lip 2026, 23:26 UTC

CytomX Therapeutics shares are higher in after-market hours, though no specific news was identified. Broader positive sentiment in European indices may be influencing investors.

21 lip 2026, 19:56 UTC

CytomX Therapeutics Inc shares are lower today, continuing a downward trend. The stock remains significantly below its 20-day moving average.

Peer Comparison

Price change

CytomX Therapeutics Inc Forecast

Price Target

By TipRanks

238.26% upside

12 Months Forecast

Average 11.67 USD 238.26%

High 16 USD

Low 6 USD

Based on 6 Wall Street analysts offering 12 month price targets forCytomX Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

6 ratings

Buy

Hold

Sell

Based on 6 analysts giving stock ratings to CytomX Therapeutics Inc - Dist in the past 3 months.

Sentiment

By Acuity

322 / 340 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About CytomX Therapeutics Inc

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna; and clinical trial collaboration and supply agreement with Merck for the evaluation of CX-801 in combination with anti-PD-1 therapy, KEYTRUDA (pembrolizumab). CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.